Documenta Ophthalmologica editorial: welcoming a broadened scope

Daphne L McCulloch¹, Ruth Hamilton^{2

3}

Affiliations

¹ School of Optometry and Vision Science, University of Waterloo, Waterloo, ON, Canada. daphne.mcculloch@uwaterloo.ca.
² Dept. of Clinical Physics and Bioengineering, Royal Hospital for Sick Children, NHS Greater Glasgow and Clyde, Glasgow, UK.
³ College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

Editorial

Daphne L McCulloch et al. Doc Ophthalmol. 2024 Dec.

. 2024 Dec;149(3):139-142.

doi: 10.1007/s10633-024-09997-4. Epub 2024 Nov 25.

Daphne L McCulloch¹, Ruth Hamilton^{2

3}

¹ School of Optometry and Vision Science, University of Waterloo, Waterloo, ON, Canada. daphne.mcculloch@uwaterloo.ca.
² Dept. of Clinical Physics and Bioengineering, Royal Hospital for Sick Children, NHS Greater Glasgow and Clyde, Glasgow, UK.
³ College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.

No abstract available

Conflict of interest statement

Declarations. Conflict of interest: The authors declare no commercial affiliations or conflicts of interest.

1. Russell S, Bennett J, Wellman JA et al (2017) Efficacy and safety of voretigene neparvovec (AAV2-hRPE65v2) in patients with RPE65-mediated inherited retinal dystrophy: a randomised, controlled, open-label, phase 3 trial. Lancet Lond Engl 390:849–860. https://doi.org/10.1016/S0140-6736(17)31868-8 - DOI
1. Ayton LN, Rizzo JF, Bailey IL et al (2020) Harmonization of outcomes and vision endpoints in vision restoration trials: recommendations from the international HOVER taskforce. Transl Vis Sci Technol 9:25. https://doi.org/10.1167/tvst.9.8.25 - DOI - PubMed - PMC
1. Leroy BP, Daly A, Héon E et al (2024) Therapies for inherited retinal dystrophies: what is enough? Drug Discov Today 29:104095. https://doi.org/10.1016/j.drudis.2024.104095 - DOI - PubMed
1. Schmetterer L, Scholl H, Garhöfer G et al (2023) Endpoints for clinical trials in ophthalmology. Prog Retin Eye Res 97:101160. https://doi.org/10.1016/j.preteyeres.2022.101160 - DOI - PubMed
1. Shore CK, Worku TL, Kahn J (2024) Rare disease innovation at the FDA-opportunities for implementation. JAMA. https://doi.org/10.1001/jama.2024.20358 - DOI - PubMed